Ocugen stock highlights Phase 3 pipeline and 2027 milestones

Published on 11/06/2026 at 22:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ocugen stock is set for key 2027 readouts after a third-quarter update. Cash and investments totaled USD 84.6 million at September 30.

Pipeline milestones shape the outlook

Ocugen has three modifier gene therapy programs in Phase 3 development.
Top-line data for OCU400 are expected in the first quarter of 2027, followed by planned regulatory activity.
The company reported USD 84.6 million in cash, restricted cash and short-term investments at September 30.

OCGN, US67577C1053, Illustration mit AI erstellt.

Ocugen reported third-quarter 2026 results and a pipeline update on Wednesday, November 4. In its company press release, the biotechnology group said all three of its modifier gene therapy programs are now in Phase 3 development.

Clinical milestones move into 2027

Ocugen said it completed enrollment of 140 patients in the Phase 3 liMeliGhT trial of OCU400 for retinitis pigmentosa. Top-line results are expected in the first quarter of 2027, followed by a planned Biologics License Application submission.

The company also reported the first patient dosed in the Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy. Top-line data from the Phase 2/3 pivotal confirmatory trial of OCU410ST for Stargardt disease are anticipated in the second quarter of 2027.

Ocugen received provisional approval and priority designation for OCU400 in The Bahamas and signed an exclusive license agreement for the Middle East and North Africa with Roots Pharmaceutical. The company said the agreement may provide up to USD 4 million in combined upfront and initial development milestone payments, up to USD 255 million in potential sales milestones and a 22 percent royalty on net sales.

Quarterly loss narrows

Revenue for the three months ended September 30 reached USD 1.951 million, compared with USD 1.752 million a year earlier. Ocugen reported a net loss of USD 3.598 million, or USD 0.01 per share, versus a net loss of USD 20.051 million, or USD 0.07 per share, in the prior-year quarter. A USD 16.562 million gain from the change in the fair value of a derivative liability contributed to the reported result.

Operating expenses rose to USD 19.704 million from USD 19.377 million, including USD 12.500 million in research and development and USD 7.204 million in general and administrative expenses. Cash, cash equivalents, restricted cash and short-term investments totaled USD 84.6 million at September 30, which management expects to extend the operating runway into 2028.

Ocugen stock traded at 0.84 euros on Lang & Schwarz at 22:41 CET on Friday, November 6, 2026.

Investors can follow the real-time quote of Ocugen stock.

The broader U.S. market context is available in the current S&P 500 market reports.

Further company developments are covered in more news and analyses on Ocugen stock.